Peer-reviewed veterinary case report
Epirubicin as part of a multi‐agent chemotherapy protocol for canine lymphoma
- Journal:
- Veterinary and Comparative Oncology
- Year:
- 2012
- Authors:
- Elliott, J. W. et al.
- Affiliation:
- Small Animal Teaching Hospital University of Liverpool Wirral UK · United Kingdom
- Species:
- dog
Abstract
AbstractThe aim of the study was to report the outcome of treatment of 97 dogs with lymphoma that received a multi‐agent chemotherapy protocol containing epirubicin as the primary anthracycline. Seventy‐five dogs received a 25‐week protocol with no maintenance phase whilst 22 dogs received a maintenance phase. Complete response rate was 96% and time to first relapse (TTR) and overall survival (OS) time for all dogs were 216 and 342 days, respectively. Dogs with T‐cell lymphoma and those classified asWHOsubstage b had significantly poorer OS times and TTR. The protocol was well tolerated with toxicity similar to doxorubicin‐containing protocols. Epirubicin as part of a multi‐agent protocol is safe and effective in the treatment of canine multicentric lymphoma. There is a high initial response rate and an overall median survival time that is similar to other published doxorubicin‐containing protocols.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://doi.org/10.1111/j.1476-5829.2011.00311.x